BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) reported full year 2025 results and a business update on Feb 26, 2026. ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO). The company achieved record GAAP and non-GAAP operating profit, completed the Astria acquisition, and received FDA approval for ORLADEYO pellets for ages 2 to <12.

BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and full year total revenue guidance of $635–$660 million.

Positive

• ORLADEYO revenue $601.8M (+38% y-o-y; +43% ex-Europe)
• Record operating profit on both GAAP and non-GAAP bases for 2025
• FDA approval for ORLADEYO oral pellets for ages 2 to <12
• Astria acquisition adds navenibart Phase 3 HAE program with strong interim data
• Maintained 2026 ORLADEYO guidance at $625–$645 million

Negative

• General & administrative expenses +45% y-o-y in 2025
• Sales & marketing expenses +16% y-o-y in 2025
• Pharmakon term loan payoff $323.7M and one-time loss on extinguishment of debt $17.3M

News Market Reaction – BCRX

+4.64%

15 alerts

+4.64% News Effect

+10.5% Peak in 48 min

+$83M Valuation Impact

$1.87B Market Cap

0.0x Rel. Volume

On the day this news was published, BCRX gained 4.64%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.5% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $83M to the company's valuation, bringing the market cap to $1.87B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ORLADEYO net revenue: $601.8 million Total revenues: $874.8 million Operating profit: $341.0 million +5 more

8 metrics

ORLADEYO net revenue $601.8 million Full year 2025; +38% y-o-y; +43% y-o-y excluding European revenue

Total revenues $874.8 million Full year 2025 GAAP total revenue

Operating profit $341.0 million Full year 2025 GAAP operating profit vs prior-year operating loss

Non-GAAP revenue $592.9 million Full year 2025 non-GAAP total revenues; +45% y-o-y

Non-GAAP operating profit $214.2 million Full year 2025 non-GAAP operating profit; +198% y-o-y

R&D expense (GAAP ex-SBC) $136.6 million Full year 2025 research and development; -5% y-o-y

Cash & investments $337.5 million Cash, cash equivalents, restricted cash and investments at Dec 31, 2025

2026 ORLADEYO guidance $625 million to $645 million Maintained full-year 2026 global net ORLADEYO revenue guidance

Market Reality Check

Price: $7.90 Vol: Volume 3,330,855 vs 20-da...

normal vol

$7.90 Last Close

Volume Volume 3,330,855 vs 20-day average 3,588,571 (slightly below typical activity). normal

Technical Shares at $7.55, trading below the 200-day MA of $8.08 and 33.24% under the 52-week high.

Peers on Argus

BCRX was down 0.79% while key peers like PAHC, BGM, and AMPH showed gains betwee...

BCRX was down 0.79% while key peers like PAHC, BGM, and AMPH showed gains between 0.87% and 2.31%, with others flat. This points to a stock-specific move rather than a sector rotation.

Previous Earnings Reports

5 past events · Latest: Jan 12 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim 2025 results	Positive	-4.2%	Preliminary 2025 ORLADEYO revenue beat guidance and 2026 outlook provided.
Nov 12	Astria Q3 update	Neutral	-0.7%	Astria standalone Q3 2025 results and update on planned BioCryst acquisition.
Nov 03	Q3 2025 earnings	Positive	-6.3%	Strong Q3 ORLADEYO growth, higher guidance, debt retirement, Astria deal agreement.
Aug 04	Q2 2025 earnings	Positive	+9.8%	Record Q2 ORLADEYO revenue, operating profit, and continued rare disease pipeline progress.
May 05	Q1 2025 earnings	Positive	+23.5%	Strong Q1 ORLADEYO growth, raised 2025 guidance and earlier‑than‑expected profitability.

Pattern Detected

Earnings and revenue updates often triggered strong moves, with some large rallies on positive quarters but also notable sell-offs after upbeat guidance and results.

Recent Company History

Across prior earnings-related announcements in 2025–early 2026, BioCryst repeatedly highlighted strong ORLADEYO growth, raised full‑year revenue guidance, and achieved profitability, while using European asset sales to retire term debt. The company also progressed plans and then execution of the Astria acquisition, adding navenibart to its HAE franchise. Market reactions varied: Q1 and Q2 2025 results drew sharp gains, Q3 2025 and the January 2026 preliminary full‑year update sold off despite positive fundamentals. Today’s full‑year 2025 report and business update extend that trajectory with finalized numbers and added pipeline detail.

Historical Comparison

+4.4% avg move · In the last 5 earnings-related releases, average move was 4.43%, with both sharp rallies and sell-of...

earnings

+4.4%

Average Historical Move earnings

In the last 5 earnings-related releases, average move was 4.43%, with both sharp rallies and sell-offs after strong ORLADEYO growth and guidance updates.

Earnings updates tracked ORLADEYO growth from Q1 through Q3 2025 and a January 2026 preliminary full-year view, culminating in today’s finalized 2025 results and updated outlook.

Market Pulse Summary

This announcement details BioCryst’s first full year of profitability, with ORLADEYO net revenue of ...

Analysis

This announcement details BioCryst’s first full year of profitability, with ORLADEYO net revenue of $601.8 million and total 2025 revenue of $874.8 million, alongside record GAAP and non-GAAP operating profits. It also highlights portfolio expansion via the Astria acquisition and promising navenibart Phase 3 and ALPHA‑SOLAR data, plus early clinical work on BCX17725. Investors may track execution against maintained 2026 revenue guidance of $625–$645 million for ORLADEYO, operating expense discipline, and progress toward planned regulatory filings by 2027.

Key Terms

phase 3, randomized, double-blind, placebo-controlled, monoclonal antibody, open-label, +2 more

6 terms

phase 3 medical

"currently in Phase 3 clinical development for HAE prophylaxis."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomized, double-blind, placebo-controlled medical

"ALPHA-ORBIT is a randomized, double-blind, placebo-controlled trial evaluating the efficacy"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

monoclonal antibody medical

"navenibart is an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

open-label medical

"New positive, interim results from the long‑term, open‑label ALPHA‑SOLAR trial show"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

klk5 inhibitor medical

"A Phase 1 trial of BCX17725, an investigational KLK5 inhibitor for the treatment"

A KLK5 inhibitor is a drug or compound that blocks the activity of KLK5, a naturally occurring protein that helps break down skin proteins and can trigger inflammation. For investors, KLK5 inhibitors matter because they represent a potential treatment approach for inflammatory skin conditions and related diseases; clinical trial results, regulatory approvals, or safety issues can strongly affect a company's development prospects and market value.

netherton syndrome medical

"KLK5 inhibitor for the treatment of Netherton syndrome, is currently enrolling"

A rare inherited skin and immune disorder that causes fragile, scaly, inflamed skin, frequent infections, and fragile or unusual hair, like a house with faulty waterproofing that lets problems in. For investors, it matters because the small patient population, severe unmet medical need, and predictable biological cause can make treatments eligible for special regulatory incentives, faster development paths, and premium pricing if a safe, effective therapy is approved.

AI-generated analysis. Not financial advice.

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)—

—Record GAAP and non-GAAP operating profit for full year 2025—

—Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million—

—Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years—

—Completed Acquisition of Astria Therapeutics—

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the full year ended December 31, 2025, and provided a business update.

“2025 was fundamentally transformative for BioCryst. We achieved full-year profitability for the first time in the company’s history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the U.S. since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve. We also advanced key business development initiatives that streamlined our operations and further strengthened our leadership position in hereditary angioedema. We entered 2026 with strong momentum, completing the acquisition of Astria Therapeutics to grow our HAE portfolio to meet the needs of more patients, while adding to our long-term growth trajectory well into the next decade,” said Charlie Gayer, President and Chief Executive Officer of BioCryst.

Business Updates

• In October 2025, the company completed the sale of its European ORLADEYO business to Neopharmed Gentili S.p.A. The transaction enabled BioCryst to simplify its operating structure and sharpen its strategic focus on its core U.S. business.
  
  
• In December 2025, the company received FDA approval for the ORLADEYO pellet formulation for patients ages 2 to <12 with HAE, making it the first and only targeted oral prophylactic therapy for children living with HAE.
  
  
• In January 2026, the company completed its acquisition of Astria Therapeutics, Inc., initially announced in October 2025. Through the transaction, BioCryst added navenibart to its HAE portfolio. Navenibart is an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein currently in Phase 3 clinical development for HAE prophylaxis.
  
  
• The navenibart Phase 3 program is currently enrolling and is on track to support regulatory filing by the end of 2027. The program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial. ALPHA-ORBIT is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of navenibart over a six-month treatment period, with dosing arms every three months (Q3M) and every six months (Q6M). After completing ALPHA-ORBIT, eligible participants may continue into the ORBIT-EXPANSE trial, in which all participants will receive navenibart in either Q3M or Q6M regimens.
  
  
• New positive, interim results from the long‑term, open‑label ALPHA‑SOLAR trial show sustained, robust HAE attack suppression with navenibart administered every three and six months. The mean and median HAE attack rate reductions from baseline were 92% and 97% in the Q3M dosing arm and 90% and 97% in the Q6M dosing arm. Long-term data up to 24 months show durable efficacy and a favorable safety profile for both dosing regimens. BioCryst will present these results in a late-breaking presentation, and other abstracts, at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, February 27–March 2, 2026.
  
  
• A Phase 1 trial of BCX17725, an investigational KLK5 inhibitor for the treatment of Netherton syndrome, is currently enrolling and has begun dosing patients. The company expects to report data from this program in up to 12 patients by the end of 2026.
  

Full Year 2025 Financial Results

Non-GAAP figures are provided with adjustments, as applicable, for the sale of the European ORLADEYO business, stock-based compensation, workforce reduction costs, and transaction-related costs. Management believes that the presentation of these non-GAAP figures can provide greater transparency into the financial results of core, ongoing operations and improve comparability across reporting periods by excluding both the impact of divestitures and other items that can vary significantly across time periods.

Total revenues were $874.8 million and operating profit was $341.0 million for the full year 2025, compared to total revenues of $450.7 million and an operating loss of $2.5 million for the full year 2024. On October 1, 2025, BioCryst sold its European ORLADEYO business, resulting in the recognition of $243.3 million of revenue related to the license of intellectual property to Neopharmed Gentili S.p.A. On a non-GAAP basis, total revenues were $592.9 million (+45% y-o-y) and operating profit was $214.2 million (+198% y-o-y).

Research and development expenses, excluding stock-based compensation expense, in 2025 were $136.6 million (-5% y-o-y) on a GAAP basis and $133.0 million (-5% y-o-y) on a non-GAAP basis. Research and development expenses included increases in program costs for BCX17725 and avoralstat driven by manufacturing and clinical activities as we advance our Phase 1 studies, as well as increased IND-enabling activities across our early-stage pipeline programs. These increases were offset by lower personnel related costs and the close out of the Factor D program.

Sales and marketing expenses, excluding stock-based compensation expense, in 2025 were $177.1 (+16% y-o-y) million on a GAAP basis and $144.1 million (+23% y-o-y) on a non-GAAP basis. The increase was driven by distribution costs primarily attributed to increased sales, process development costs, the transition of certain safety and regulatory support roles from research and development due to commercial progression, pediatric launch support and other compensation expenses related to strong ORLADEYO sales performance.

General and administrative expenses, excluding stock-based compensation expense, in 2025 were $116.0 million (+45% y-o-y) on a GAAP basis and $85.0 million (+21% y-o-y) on a non-GAAP basis. The increase was driven by compensation, headcount growth in certain functions, and the transition of certain quality support roles from research and development to general and administrative in connection with ORLADEYO’s continued commercial progression.

Stock-based compensation increased due to a modification to extend the post-termination exercise period of certain vested stock option awards at the time of retirement for certain individuals to the original expiration date and an increase in restricted stock unit awards granted.

Interest expense was $78.9 million for the full year 2025 (-20% y-o-y). The decrease was primarily driven by the payoff of the Pharmakon Term Loan in 2025 and a decrease in the effective interest rate during the period in which the debt was outstanding in 2025. The payoff of the Pharmakon Term Loan, totaling $323.7 million, resulted in a one-time loss on extinguishment of debt of $17.3 million for the full year 2025.

Other income was $12.1 million for the full year 2025, which was primarily comprised of the impacts from the sale of our European ORLADEYO business. There was no other income for the full year 2024.

Cash, cash equivalents, restricted cash and investments totaled $337.5 million at December 31, 2025. Net cash utilization for the full year 2025 was $5.4 million. Excluding the impacts of the payoff of the Pharmakon loan and related expenses totaling $333.6 million and the net proceeds from the sale of our European ORLADEYO business to Neopharmed Gentili S.p.A. totaling $243.0 million, there was $85.2 million of cash generated during 2025.

Financial Outlook for 2026
The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million.

The company also maintained its expectation for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $450 million and $470 million.

Item	As of February 26, 2026	As of January 12, 2026
ORLADEYO revenue	Unchanged	$625 million to $645 million
Total revenue	Unchanged	$635 million to $660 million
Non-GAAP operating expense	Unchanged	$450 million to $470 million

Conference Call and Webcast
BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Non-GAAP Financial Measures
The information furnished in this release and the accompanying tables includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP.”

We believe providing these non-GAAP measures, which show our results with these items adjusted, is valuable and useful since they allow management and investors to better understand the company’s financial performance in the absence of certain non-cash items such as stock-based compensation and certain special events and allow investors to more accurately understand our current and past period results and more easily compare them to future results. These non-GAAP measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue, operating income, net income, and earnings per share.

Our references to non-GAAP operating income or profit, ORLADEYO net revenue, total revenue, research and development expenses, sales and marketing expenses, and general and administrative expenses constitute non-GAAP financial measures. These non-GAAP financial measures are calculated using our GAAP results, adjusted to show the results without including, as applicable, revenues and expenses associated with our European ORLADEYO business, license revenue related to the license of intellectual property to Neopharmed Gentili S.p.A., transaction-related costs, non-cash stock-based compensation expense, and workforce reduction expenses. A reconciliation between each non-GAAP financial measure and its respective closest equivalent GAAP financial measure is provided in the tables below.

We also provide our non-GAAP operating expense outlook for full year 2026, which refers to our expected GAAP operating expense, excluding stock-based compensation, restructuring and transaction-related costs. We have not provided a reconciliation against the comparable forward-looking GAAP measure because we are unable to predict with reasonable certainty the full amount of stock-based compensation expense or restructuring or transaction-related costs for the full year 2026 without unreasonable effort. Stock-based compensation expense is uncertain and depends on various factors, including our future hiring and retention needs, as well as the future fair market value of our common stock, which is difficult to predict and subject to change. In addition, we are unable to predict with reasonable certainty the full amount of restructuring and transaction-related costs as the related costs are dependent on various factors that have not yet or have only recently occurred. The actual amount of stock-based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements, including expected full year 2026 revenue and operating expenses, and expectations regarding pipeline development timing and BioCryst’s growth trajectory. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans as described herein, including meeting the expected timelines; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission (the “SEC”), specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com 

Media:
media@biocryst.com 

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL SUMMARY
(In thousands, except per share)

Statements of Operations (Unaudited)

	Three Months Ended December 31,								Twelve Months Ended December 31,
		2025				2024				2025				2024
Revenues:
ORLADEYO	$	151,682			$	124,186			$	601,839			$	437,660
License revenue		243,980				—				243,980				—
Other revenues		10,893				7,348				29,018				13,052
Total revenues		406,555				131,534				874,837				450,712
Expenses:
Cost of product sales		9,522				6,094				19,075				12,269
Research and development		40,867				49,441				166,126				174,638
Selling, general and administrative		95,781				80,507				348,647				266,348
Total operating expenses		146,170				136,042				533,848				453,255
Income (loss) from operations		260,385				(4,508	)			340,989				(2,543	)
Other income (expense):
Interest income		2,890				3,570				10,668				14,746
Interest expense		(14,135	)			(24,449	)			(78,872	)			(98,516	)
Foreign currency losses, net		(125	)			(604	)			(152	)			(641	)
Loss on extinguishment of debt		(10,421	)			—				(17,332	)			—
Other income		9,423				—				12,090				—
Total other expense, net		(12,368	)			(21,483	)			(73,598	)			(84,411	)
Income (loss) before income taxes		248,017				(25,991	)			267,391				(86,954	)
Income tax expense		2,172				804				3,530				1,927
Net income (loss)	$	245,845			$	(26,795	)		$	263,861			$	(88,881	)
Net income (loss) per common share: basic	$	1.17			$	(0.13	)		$	1.26			$	(0.43	)
Weighted average shares of common stock outstanding: basic		210,969				207,381				209,893				206,696
Net income (loss) per common share: diluted	$	1.12			$	(0.13	)		$	1.21			$	(0.43	)
Weighted average shares of common stock outstanding: diluted		219,263				207,381				218,581				206,696

Balance Sheet Data (in thousands)

	December 31,
	2025 (unaudited)				2024 (Note 1)
Cash, cash equivalents and investments	$	335,911			$	341,173
Restricted cash		1,601				1,610
Receivables		106,818				79,069
Total assets		514,158				490,420
Secured term loan		—				314,869
Royalty financing obligation		465,688				513,729
Accumulated deficit		(1,506,179	)			(1,770,040	)
Stockholders’ deficit		(119,153	)			(475,934	)
Shares of common stock outstanding		213,060				208,543
Note 1: Derived from audited financial statements.

Reconciliations of Non-GAAP Income (Loss) from Operations (in thousands)

	Twelve Months Ended December 31, 2025
	U.S. GAAP			European ORLADEYO Business1				Other Non-GAAP Adjustments2			Non-GAAP
Revenues:
ORLADEYO:
U.S.	$	548,779		$	—			$	—		$	548,779
Outside of U.S.		53,060			38,658				—			14,402
Total ORLADEYO		601,839			38,658				—			563,181
License revenue		243,980			—				243,271			709
Other revenues		29,018			—				—			29,018
Total revenues		874,837			38,658				243,271			592,908
Expenses:
Cost of product sales		19,075			2,465				9			16,601
Research and development (excluding stock-based compensation)		136,616			1,539				2,040			133,037
Sales and marketing (excluding stock-based compensation)		177,085			30,495				2,502			144,088
General and administrative (excluding stock-based compensation)		116,006			8,089				22,912			85,005
Stock-based compensation		85,066			—				85,066			—
Total operating expenses		533,848			42,588				112,529			378,731
Income (loss) from operations	$	340,989		$	(3,930	)		$	130,742		$	214,177
1Represents revenues and expenses associated with our European ORLADEYO business which was sold to Neopharmed Gentili S.p.A. on October 1, 2025.
2Reflects the following non-GAAP adjustments for the twelve months ended December 31, 2025:
License revenue related to the license of intellectual property to Neopharmed Gentili S.p.A.											$	243,271
Transaction-related costs											$	21,149
Workforce reduction expense											$	6,314
Stock-based compensation											$	85,066

	Twelve Months Ended December 31, 2024
	U.S. GAAP				European ORLADEYO Business1				Other Non-GAAP Adjustments2				Non-GAAP
Revenues:
ORLADEYO:
U.S.	$	385,961			$	—			$	—			$	385,961
Outside of U.S.		51,699				43,130				—				8,569
Total ORLADEYO		437,660				43,130				—				394,530
License revenue		—				—				—				—
Other revenues		13,052				—				—				13,052
Total revenues		450,712				43,130				—				407,582
Expenses:
Cost of product sales		12,269				2,879				—				9,390
Research and development (excluding stock-based compensation)		143,353				2,723				1,201				139,429
Sales and marketing (excluding stock-based compensation)		152,166				35,252				—				116,914
General and administrative (excluding stock-based compensation)		80,054				9,999				63				69,992
Stock-based compensation		65,413				—				65,413				—
Total operating expenses		453,255				50,853				66,677				335,725
Income (loss) from operations	$	(2,543	)		$	(7,723	)		$	(66,677	)		$	71,857
1Represents revenues and expenses associated with our European ORLADEYO business which was sold to Neopharmed Gentili S.p.A. on October 1, 2025.
2Reflects the following non-GAAP adjustments for the twelve months ended December 31, 2024:
Workforce reduction expense													$	1,264
Stock-based compensation													$	65,413

	Three Months Ended December 31, 2025
	U.S. GAAP				European ORLADEYO Business1				Other Non-GAAP Adjustments2				Non-GAAP
Revenues:
ORLADEYO:
U.S.	$	146,725			$	—			$	—			$	146,725
Outside of U.S.		4,957				—				—				4,957
Total ORLADEYO		151,682				—				—				151,682
License revenue		243,980				—				243,271				709
Other revenues		10,893				—				—				10,893
Total revenues		406,555				—				243,271				163,284
Expenses:
Cost of product sales		9,522				—				9				9,513
Research and development (excluding stock-based compensation)		35,731				—				2,040				33,691
Sales and marketing (excluding stock-based compensation)		39,712				—				2,185				37,527
General and administrative (excluding stock-based compensation)		37,412				—				13,296				24,116
Stock-based compensation		23,793				—				23,793				—
Total operating expenses		146,170				—				41,323				104,847
Income (loss) from operations	$	260,385			$	—			$	201,948			$	58,437
1No revenues or expenses for the three months ended December 31, 2025, as we sold our European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025.
2Reflects the following non-GAAP adjustments for the three months ended December 31, 2025:
License revenue related to the license of intellectual property to Neopharmed Gentili S.p.A.													$	243,271
Transaction-related costs													$	11,216
Workforce reduction expense													$	6,314
Stock-based compensation													$	23,793
	Three Months Ended December 31, 2024
	U.S. GAAP				European ORLADEYO Business1				Other Non-GAAP Adjustments2				Non-GAAP
Revenues:
ORLADEYO:
U.S.	$	106,974			$	—			$	—			$	106,974
Outside of U.S.		17,212				12,957				—				4,255
Total ORLADEYO		124,186				12,957				—				111,229
License revenue		—				—				—				—
Other revenues		7,348				—				—				7,348
Total revenues		131,534				12,957				—				118,577
Expenses:
Cost of product sales		6,094				743				—				5,351
Research and development (excluding stock-based compensation)		39,079				143				—				38,936
Sales and marketing (excluding stock-based compensation)		39,702				9,833				—				29,869
General and administrative (excluding stock-based compensation)		29,828				3,644				—				26,184
Stock-based compensation		21,339				—				21,339				—
Total operating expenses		136,042				14,363				21,339				100,340
Income (loss) from operations	$	(4,508	)		$	(1,406	)		$	(21,339	)		$	18,237
1Represents revenues and expenses associated with our European ORLADEYO business which was sold to Neopharmed Gentili S.p.A. on October 1, 2025.
2Reflects the following non-GAAP adjustment for the three months ended December 31, 2024:
Stock-based compensation													$	21,339

FAQ

How much ORLADEYO revenue did BioCryst (BCRX) report for full year 2025?

BioCryst reported $601.8 million in ORLADEYO net revenue for full year 2025. According to the company, that equals +38% year-over-year and +43% y-o-y excluding European ORLADEYO after the October 1, 2025 sale.

What guidance did BioCryst (BCRX) give for ORLADEYO revenue in 2026?

BioCryst maintained full year 2026 ORLADEYO revenue guidance of $625–$645 million. According to the company, total 2026 revenue guidance including RAPIVAB is expected to be $635–$660 million.

What was BioCryst’s (BCRX) cash position and notable debt activity at year-end 2025?

Cash, cash equivalents, restricted cash and investments were $337.5 million at December 31, 2025. According to the company, it paid off the Pharmakon term loan ($323.7 million) and recorded a $17.3 million loss on extinguishment.

What clinical progress did BioCryst (BCRX) report after acquiring Astria in Jan 2026?

BioCryst added navenibart and reported strong interim ALPHA-SOLAR results showing mean HAE attack reductions ~92% (Q3M) and ~90% (Q6M). According to the company, the Phase 3 program is enrolling and on track for a 2027 regulatory filing.

What approvals did BioCryst (BCRX) receive in December 2025 related to ORLADEYO?

BioCryst received FDA approval for ORLADEYO oral pellets for patients ages 2 to <12 with HAE. According to the company, this makes ORLADEYO the first targeted oral prophylactic therapy for children with HAE.